SNV1521 is a novel PARP-1 selective inhibitor and first data were presented at ESMO 20225. The study demonstrates that this novel PARP-1 selective inhibitor has an improved tolerability profile compared to first-generation PARP inhibitors. And also in terms of response, we observed that some patients, especially with alteration of the homologous recombination pathway that were not pre-exposed to PARP inhibitors, achieved very good benefit on this drug...
SNV1521 is a novel PARP-1 selective inhibitor and first data were presented at ESMO 20225. The study demonstrates that this novel PARP-1 selective inhibitor has an improved tolerability profile compared to first-generation PARP inhibitors. And also in terms of response, we observed that some patients, especially with alteration of the homologous recombination pathway that were not pre-exposed to PARP inhibitors, achieved very good benefit on this drug. And in particular, I believe that the safety profile of SME-1521 together with this preliminary sign of activity allow for further development of this drug either as monotherapy or in combination therapy with novel agents including antibody drug conjugates chemotherapy and targeted therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
